Development of a Complete Human Anti-human Transferrin Receptor C Antibody As a Novel Marker of Oral Dysplasia and Oral Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2014 Jun 4

PMID 24890018

Citations 15

Authors

Kentaro Nagai

Shingo Nakahata

Shunsuke Shimosaki

Tomohiro Tamura

Yuudai Kondo

Takashi Baba

Tomohiko Taki

Masafumi Taniwaki

Gene Kurosawa

Yukio Sudo

Seiji Okada

Sumio Sakoda

Kazuhiro Morishita

Affiliations

Soon will be listed here.

Abstract

Oral squamous cell carcinoma (OSCC) is the sixth most common cancer worldwide. Up to 20% of oral dysplasia cases have been suggested to undergo malignant transformation to OSCC; however, there are no methods to predict OSCC development. In this study, to identify the genes associated with oral dysplasia progression, we performed genomic copy number analyses of genomic DNA samples isolated from primary oral dysplasia and OSCC via the microdissection method and found elevated expression of transferrin receptor C (TfR1/TFRC) with genomic amplification in oral dysplasia and OSCC. The expression rate of TFRC in OSCC was significantly higher than that in dysplasia, suggesting that OSCC disease progression might be related to TFRC expression. Additionally, we investigated the in vitro and in vivo impacts of a newly established anti-human TFRC monoclonal antibody, which was isolated from a human cDNA library using the phage-display method, on cell proliferation and survival. The anti-TFRC antibody blocked the interaction between transferrin and TFRC and consequently inhibited iron uptake, leading to the iron deprivation-mediated suppression of cell growth and induction of apoptosis. Moreover, we demonstrated that the anti-TFRC antibody efficiently inhibited tumor growth in a murine xenograft OSCC model. Therefore, we suggest our developed complete human anti-human TFRC antibody as a useful, novel treatment for oral dysplasia and OSCC.

Citing Articles

Transferrin Receptor 2 in Canine Testicular Tumors: An Emerging Key Role in Seminomas.

Leandri R, Buonocore S, Power K Animals (Basel). 2025; 15(2).

PMID: 39858264 PMC: 11758335. DOI: 10.3390/ani15020264.

Transferrin receptor uptakes iron from tumor-associated neutrophils to regulate invasion patterns of OSCC.

Si Q, Wang Y, Lu W, Liu Z, Song Y, Chen S Cancer Immunol Immunother. 2025; 74(2):43.

PMID: 39751915 PMC: 11699170. DOI: 10.1007/s00262-024-03894-0.

Evaluation of salivary transferrin in patients with oral squamous cell carcinoma.

Tavakoli F, Ghavimi M, Fakhrzadeh V, Abdolzadeh D, Afshari A, Eslami H Clin Exp Dent Res. 2023; 10(1):e809.

PMID: 37964689 PMC: 10860556. DOI: 10.1002/cre2.809.

NCBP2 and TFRC are novel prognostic biomarkers in oral squamous cell carcinoma.

Arora R, Haynes L, Kumar M, McNeil R, Ashkani J, Nakoneshny S Cancer Gene Ther. 2023; 30(5):752-765.

PMID: 36635327 PMC: 10191846. DOI: 10.1038/s41417-022-00578-8.

Secreted protein markers in oral squamous cell carcinoma (OSCC).

Mumtaz M, Bijnsdorp I, Bottger F, Piersma S, Pham T, Mumtaz S Clin Proteomics. 2022; 19(1):4.

PMID: 35130834 PMC: 8903575. DOI: 10.1186/s12014-022-09341-5.

References

Kon S, Minegishi N, Tanabe K, Watanabe T, Funaki T, Wong W . Smap1 deficiency perturbs receptor trafficking and predisposes mice to myelodysplasia. J Clin Invest. 2013; 123(3):1123-37. PMC: 3582118. DOI: 10.1172/JCI63711. View

Kurosawa G, Sumitomo M, Ukai Y, Subere J, Muramatsu C, Eguchi K . Selection and analysis of anti-cancer antibodies for cancer therapy obtained from antibody phage library. Cancer Sci. 2010; 102(1):175-81. DOI: 10.1111/j.1349-7006.2010.01739.x. View

Hentze M, Muckenthaler M, Andrews N . Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004; 117(3):285-97. DOI: 10.1016/s0092-8674(04)00343-5. View

Ghosh A, Ghosh S, Maiti G, Sabbir M, Zabarovsky E, Roy A . Frequent alterations of the candidate genes hMLH1, ITGA9 and RBSP3 in early dysplastic lesions of head and neck: clinical and prognostic significance. Cancer Sci. 2010; 101(6):1511-20. PMC: 11159363. DOI: 10.1111/j.1349-7006.2010.01551.x. View

Nagatsuka H, Siar C, Tsujigiwa H, Naomoto Y, Han P, Gunduz M . Heparanase and cyclooxygenase-2 gene and protein expressions during progression of oral epithelial dysplasia to carcinoma. Ann Diagn Pathol. 2012; 16(5):354-61. DOI: 10.1016/j.anndiagpath.2012.02.004. View

Ono A, Hattori S, Kariya R, Iwanaga S, Taura M, Harada H . Comparative study of human hematopoietic cell engraftment into BALB/c and C57BL/6 strain of rag-2/jak3 double-deficient mice. J Biomed Biotechnol. 2011; 2011:539748. PMC: 3035318. DOI: 10.1155/2011/539748. View

Smith J, Rattay T, McConkey C, Helliwell T, Mehanna H . Biomarkers in dysplasia of the oral cavity: a systematic review. Oral Oncol. 2009; 45(8):647-53. DOI: 10.1016/j.oraloncology.2009.02.006. View

Van der Linden N, van Gils C, Pescott C, Buter J, Uyl-de Groot C . Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial results. Eur Arch Otorhinolaryngol. 2013; 271(6):1673-8. DOI: 10.1007/s00405-013-2646-2. View

Shen X, Zhu H, He F, Xing W, Li L, Liu J . An anti-transferrin receptor antibody enhanced the growth inhibitory effects of chemotherapeutic drugs on human non-hematopoietic tumor cells. Int Immunopharmacol. 2008; 8(13-14):1813-20. DOI: 10.1016/j.intimp.2008.08.022. View

10.

Stott-Miller M, Houck J, Lohavanichbutr P, Mendez E, Upton M, Futran N . Tumor and salivary matrix metalloproteinase levels are strong diagnostic markers of oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2011; 20(12):2628-36. PMC: 3237810. DOI: 10.1158/1055-9965.EPI-11-0503. View

11.

Kondo Y, Nagai K, Nakahata S, Saito Y, Ichikawa T, Suekane A . Overexpression of the DNA sensor proteins, absent in melanoma 2 and interferon-inducible 16, contributes to tumorigenesis of oral squamous cell carcinoma with p53 inactivation. Cancer Sci. 2012; 103(4):782-90. PMC: 7659186. DOI: 10.1111/j.1349-7006.2012.02211.x. View

12.

Chen C, Mendez E, Houck J, Fan W, Lohavanichbutr P, Doody D . Gene expression profiling identifies genes predictive of oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2008; 17(8):2152-62. PMC: 2575803. DOI: 10.1158/1055-9965.EPI-07-2893. View

13.

Brooks M, Bennett R, Weaver A, Sebo T, Eckert S, Strehler E . Human Calmodulin-Like Protein CALML3: A Novel Marker for Normal Oral Squamous Mucosa That Is Downregulated in Malignant Transformation. Int J Dent. 2013; 2013:592843. PMC: 3723245. DOI: 10.1155/2013/592843. View

14.

Leemans C, Braakhuis B, Brakenhoff R . The molecular biology of head and neck cancer. Nat Rev Cancer. 2010; 11(1):9-22. DOI: 10.1038/nrc2982. View

15.

Daniels T, Delgado T, Rodriguez J, Helguera G, Penichet M . The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006; 121(2):144-58. DOI: 10.1016/j.clim.2006.06.010. View

16.

Akahori Y, Kurosawa G, Sumitomo M, Morita M, Muramatsu C, Eguchi K . Isolation of antigen/antibody complexes through organic solvent (ICOS) method. Biochem Biophys Res Commun. 2008; 378(4):832-5. DOI: 10.1016/j.bbrc.2008.11.129. View

17.

Silverman Jr S, Gorsky M, Lozada F . Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer. 1984; 53(3):563-8. DOI: 10.1002/1097-0142(19840201)53:3<563::aid-cncr2820530332>3.0.co;2-f. View

18.

Pozzi V, Sartini D, Morganti S, Giuliante R, Di Ruscio G, Santarelli A . RNA-mediated gene silencing of nicotinamide N-methyltransferase is associated with decreased tumorigenicity in human oral carcinoma cells. PLoS One. 2013; 8(8):e71272. PMC: 3749215. DOI: 10.1371/journal.pone.0071272. View

19.

Kaur J, Sawhney M, Dattagupta S, Shukla N, Srivastava A, Walfish P . Clinical significance of altered expression of β-catenin and E-cadherin in oral dysplasia and cancer: potential link with ALCAM expression. PLoS One. 2013; 8(6):e67361. PMC: 3696121. DOI: 10.1371/journal.pone.0067361. View

20.

Lenarduzzi M, Hui A, Yue S, Ito E, Shi W, Williams J . Hemochromatosis enhances tumor progression via upregulation of intracellular iron in head and neck cancer. PLoS One. 2013; 8(8):e74075. PMC: 3753261. DOI: 10.1371/journal.pone.0074075. View